Alvotech maintains 2026 approval targets following routine FDA audit
Alvotech (NASDAQ:ALVO) announced Monday that the U.S. Food and Drug Administration (FDA) has completed a routine cGMP (current Good Manufacturing Practice) surveillance inspection at its Reykjavik, Iceland, facility.


-640x360.webp&w=3840&q=75)







